Award Number: W81XWH-11-1-0841

TITLE: National Trauma Institute: A National Coordinating Center for Trauma Research Funding

PRINCIPAL INVESTIGATOR: Donald Jenkins, M.D.

CONTRACTING ORGANIZATION: National Trauma Institute
San Antonio, TX 78230

REPORT DATE: October 2012

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The purpose of this grant is to support a national coordinating center for trauma research funding, and provide a forum for dissemination of trauma research information. The infrastructure/process is streamlined and efficient leading to the selection of research projects based on a solid scientific, peer review of submitted research proposals and subsequent conduct of important clinical trauma research that will impact patient outcomes.
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>14</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>14</td>
</tr>
<tr>
<td>Conclusion</td>
<td>14</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>15</td>
</tr>
</tbody>
</table>
INTRODUCTION

The National Trauma Institute (NTI) proposed to utilize $3,845,000 in congressional funding to continue and broaden work begun by NTI in previous congressional special interest funding proposals. NTI’s objective is to distribute and manage funding for peer-reviewed research projects for areas of greatest impact in trauma, in order to change practice to save lives and improve outcomes for those affected by trauma, and to disseminate research findings to the trauma community.

BODY

Statement of Work

A. The contract will support a national coordinating center for trauma research funding.

1) Requests for proposals (RFP) based on areas of scientific merit in trauma and emergency or critical care will be prepared and issued.

2) NTI Board Science Committee will score proposals according to scientific merit, clinical impact, ability to perform the research, innovation, and military relevance.

3) NTI Board will update trauma research subject areas based upon the impact on survival or care of patients, existing funding, and funding availability annually.

4) NTI will perform Award management and compliance to include all appropriate USAMRMC HRPO requirements.

5) NTI will provide research funding for proposals that seek to address areas of urgent need in the treatment of trauma.

B. The contractor will provide multiple meeting forums for progress towards methods for military-civilian transfer of medical advances, and development of clinical protocols from promising currently funded pilot studies, as determined by the Science Committee. These meetings will include military and civilian researchers.

A. National Coordinating Center for Trauma Research Funding.

Tasks 1-3: Requests for proposals, scientific peer review, and update trauma research subject areas

The NTI Science Committee conducted scientific peer-review of research proposals submitted under the Request for Proposals (RFP). Clinical or translational research studies were given priority. NTI utilized an online software product to facilitate the submission, management and review of proposals. The Letter of Intent/Pre-proposal Form, Full Proposal Form, and Science Committee evaluation forms developed by NTI were used in this RFP cycle. The
national request for proposals attracted 92 pre-proposals from across the United States (Fig. 1).

![Figure 1. National locations from which pre-proposals were received](image)

The pre-proposals were reviewed and 22 investigators were invited to submit full proposals (Fig. 2).

![Figure 2. National locations from which full proposals were received](image)

The 22 full proposals were reviewed by all members of the Science Committee, and scores were submitted and compiled. A face-to-face evaluation and review meeting was held in to make final award recommendations. Proposals were evaluated on the following criteria: relevance to NTI research objectives, scientific excellence, clinical relevance and impact, multicenter collaboration, military relevance, innovation, potential for follow-on studies, and feasibility of completing the objectives in one-year funding period. Nine proposals were recommended by the Science Committee and approved by the full Board of Directors for funding. Figures 3 and 4 show the locations of the lead sites and participating sites for each study, respectively.
NTI Board meetings occur every two months. These are the forums where updates to trauma research subject areas based upon the impact on survival or care of patients, existing funding, and funding availability is discussed.

**Task 4-5: Perform Award management and compliance to include all appropriate USAMRMC HRPO requirements and provide research funding.**

There are 9 research projects, including the Delayed Splenic Rupture after Non-Operative Management of Blunt Splenic Injury (PI: Dr Ben Zarzaur). The latter is an American Association for the Surgery of Trauma (AAST) Multi-Institutional Prospective Trial and has eleven research sites. NTI subcontracted with each participating site for this award only. Therefore, there were a total of 19 research subcontracts to be executed. Subcontracts are not executed until the site has HRPO approval. Subcontracts with 18 of the 19 research sites were completed in Year 1.

HRPO compliance is maintained by immediate submission of all required documents to HRPO to obtain initial approval. Throughout the research study, all regulatory compliance activities, such as amendments, continuing reviews, protocol deviations, adverse events, study close out upon study completion are managed per the guidelines set forth by the HRPO.
An eighteen month No Cost Extension for the overall contract between NTI and USAMRMC was approved through March 2014, effective 9/28/2012.

Provide research funding for proposals that seek to address areas of urgent need in the treatment of trauma.

Nine proposals were recommended by the Science Committee and approved by the Board of Directors for funding. Progress of these projects is described below:

**Project 1:**
**Project Title:** Acute Lung Injury Ventilation Evaluation (ALIVE) Trial  
**Principal Investigator:** Suresh Agarwal, MD  
**Lead site:** Medical College of Wisconsin.

**Participating Sites:** Boston Medical Center (BMC), San Antonio Military Medical Center (SAMMC), Massachusetts General, University of Maryland Medical Center, University of Mass Memorial Medical Center, University of Penn, Harborview Medical Center, and University of Texas Health Science Center at San Antonio (UTHSCSA)

**Lay Abstract:** Acute lung injury (ALI) from treatment of patients with severe injuries remains a significant healthcare burden for both the military and civilian populations. It accounts for over 75,000 deaths annually, is associated with numerous complications to the lungs and other organs, and places a considerable financial burden upon the healthcare system. Many studies have attempted to demonstrate techniques to treat ALI. However, these have met with extremely limited success and still result in mortality in 30-40% of those afflicted. Mechanical ventilation (respirator) techniques remain the only accepted treatment therapy of these patient groups, but these are also associated with problems including segmental lung collapse, increased time on the ventilator, and increased incidence of pneumonia. Novel, non-experimental, therapies of managing ventilators exist but have not been compared with traditional therapy in regards to management of patients with ALI. One method, airway pressure release ventilation (APRV), provides greater patient respiratory control, better oxygenation, less sedative use, and decreased incidence of pneumonia. This proposed study is a randomized examination of biomarkers of patients with ALI using two ventilator modes: APRV and ARDSNet (traditional modality for management of ALI). Our long term goal is to improve health outcomes of patients with ALI and ARDS and gain a better understanding of its pathogenesis, prevention, and treatment.

**Progress Reported:** HRPO Log #A-16977.6. Due to the Principal Investigator’s relocation, the lead site changed from Boston Medical Center to the Medical College of Wisconsin and Boston Medical Center was retained as a participating site. NTI was notified of this move and lead site change in July 2012. Prior to this notification all IRB approved documents from Boston Medical Center were submitted to HRPO on 10/11/11. HRPO recommendations for revisions were received on 3/6/12 and the recommended revisions were made.

In light of the lead site change, approval of the newly identified participating site, Boston Medical Center, is on hold until the lead site, Medical College of Wisconsin is approved.

**Project 2:**
**Project Title:** The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy that Sustain Intracranial Hemorrhage  
**Principal Investigator:** Mark Cipolle, MD  
**Lead Site:** Christiana Health Care System, Newark DE
Lay Abstract: Brain hemorrhage is the most important reason for death and disability after injury or stroke. Many patients at this site are using antiplatelet medications that inhibit the early steps in blood clotting. While these medications are very effective in reducing the risk of heart attack and stroke, bleeding is an important side effect. While these medications do not cause brain hemorrhage, it is likely that they worsen a hemorrhage once it has occurred. In this first year this site plans to perform a pilot trial of 40 patients at our center in preparation of performing a multicenter, randomized, controlled clinical trial to test the potential benefit and safety of providing a platelet transfusion to patients suffering a brain hemorrhage while taking antiplatelet medication. Patients on antiplatelet therapy that have a brain hemorrhage seen on Computed Tomography (CT) scan within 4 hours of injury or onset of symptoms will be eligible. They will then be randomized (coin flip) to receive either a platelet transfusion or an infusion of salt water (control). Another CT scan will be obtained in 24 hours and we will compare the change in hemorrhage between groups. Other outcome measures tracked will be improvement in neurologic outcome and the development of a new heart attack, stroke or blood clot out to 90 days. We will also examine platelet function in all patients using a bedside test. An institutional review board and data safety monitoring board will oversee the trial to ensure patient safety.

Progress: HRPO Log #A-16977.5. This project was approved by HRPO on 4/4/12. Two quarters of subject enrollment has been completed with 198 subject screened and two subjects having been enrolled. The inclusion criterion of “traumatic brain hemorrhage only” has impacted the number of eligible subjects. Dr Cipolle and his research team continue to look at ways to enhance the screening and enrollment process.

Project 3:
Project Title: Transfusion of Stored Fresh Whole Blood (FWB) in a Civilian Trauma Center: A Prospective Evaluation of Feasibility and Outcomes
Principal Investigator: Henry Gill Cryer, MD
Lead Site: University of California, Los Angeles (UCLA)
Lay Abstract: Resuscitation protocols for trauma patients presenting with significant bleeding utilize administration of components of blood including Red Blood Cells (RBCs), plasma, and platelets. Despite improvements in emergency surgery and critical care, trauma patients with severe bleeding still suffer from high incidence of complications and death compared to patients that require fewer or no transfusions. Recent studies from military centers indicate that transfusion of Fresh Whole Blood may be more beneficial than individual blood components in patients with severe hemorrhage. This has not been studied in civilian trauma patients mainly due to the technical difficulties and costs. This site proposes a feasibility and hospital outcomes study using FWB (storage time of 5 days) for resuscitating trauma patients with significant bleeding. A cohort of adult trauma patients presenting with severe hemorrhage and receiving resuscitation with FWB will be prospectively compared to a control group of patients receiving standard component therapy. The shelf-life of whole blood cost of treatment, levels of clotting and inflammatory markers in patient’s blood samples, as well as the incidence of persistent bleeding, development of blood clots, infections, and mortality will be compared between the two groups. This study is designed to determine whether FWB transfusions are feasible in a civilian trauma center and to determine whether resuscitation using FWB is superior to component therapy in patients with severe hemorrhage.

Progress Reported: HRPO log #A-16977.1. HRPO approval was received on 3/6/2012. This project is in the third quarter. The investigator is in the process of purchasing equipment
(Thrombelastography (TEG) and Thrombinoscope) for the laboratory analysis of blood samples. As of the last quarterly report received from Dr. Cryer on 9/6/2012, a confirmed installation date for the Thrombinoscope was set for 10/4/2012 and the installation date for the TEG machine is being coordinated. Once both machines are installed, testing of Fresh Whole Blood Samples will begin.

**Project 4:**
**Project Title:** Detection and Management of Non-Compressible Hemorrhage by Vena Cava Ultrasonography

**Principal Investigator:** Jay Doucet, MD

**Lead Site:** University of California at San Diego (UCSD)

**Participating Sites:** University of Utah, Emory University, and Penn State/Hershey Medical Center.

**Lay Abstract:** This is a study of patients admitted with major traumatic injuries admitted in shock otherwise known as low blood pressure. Such patients may develop inadequate circulation to the organs as a result of internal blood loss. Early detection of internal blood loss can be difficult as physical examination alone may not detect significant internal blood loss. After traumatic injury, some patients with bleeding will develop shock. The inferior vena cava is the large vein draining blood from the lower body to the heart. The inferior vena cava stores blood and is known to empty when the patient has had significant blood loss. The vena cava diameter can be seen using ultrasound. This study intends to perform ultrasound to examine the vena cava diameter on patients just after arriving at a Trauma Center with major trauma and shock before and after giving fluids. This site proposes that measuring the inferior vena cava in this manner can predict those patients who are likely to continue bleeding and require interventions such as surgery. Early detection in these patients may avoid delays in treatment, complications and excess mortality. Because this examination is done with handheld ultrasound machines, it could be done outside hospitals and in military combat casualty care.

**Progress Reported:** HRPO Log#A-16977.2a. HRPO approval of the lead site was received on 11/17/2011. All other participating sites are in the process of obtaining local IRB approval. Once local IRB approval is obtained, HRPO approval will be sought for the participating sites. The lead site has completed three quarters. A contractor was secured to host the American Association for the Surgery of Trauma (AAST) Multi-Institutional Trials data collection website. The website is fully functional and available for data entry. The lead site has enrolled seven subjects as of the last quarterly report dated 8/27/12. Due to the low enrollment, the Principal Investigator proposed an amendment to modify the inclusion/exclusion criteria to capture additional subjects. This amendment is currently under review at the University of California San Diego’s IRB.

**Project 5:**
**Project Title:** Methicillin-Resistant Staphylococcus aureus in a Trauma Population: Does Decolonization Prevent Infection?

**Principal Investigator:** Robert Maxwell, MD

**Lead Site:** University of Tennessee Health Science Center at Chattanooga

**Participating Sites:** University of Tennessee Health Science Center at Memphis, and Vanderbilt University. Vanderbilt’s contribution to this project is limited to research/lab testing.
Vanderbilt will not be engaged in human research and an “Exempt” determination has been forwarded and accepted by the HRPO office.

**Lay Abstract:** Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of infection in both healthcare and community settings and is one of the most common causes of healthcare-associated infections. In a cohort of 355 consecutive trauma admissions, this site has shown a 10.1% incidence of MRSA colonization by nasal swab DNA testing. Of the patients colonized, 33.3% developed an invasive MRSA infection, compared with 6% of the noncolonized patients. The colonized patients who developed invasive MRSA infections required significantly longer days of mechanical ventilation and had higher mortality. Dr Maxwell therefore hypothesize that identifying trauma patients colonized with MRSA on admission and employing decolonization regimen will reduce the incidence of invasive MRSA infection. All trauma patients admitted to the Intensive Care Unit will have nasal swabs performed to determine if they are colonized with MRSA. Patients who are colonized will be randomized to receive either decolonization treatment with Bactroban ointment applied to both nostrils and baths using antibacterial soap or they will have a placebo ointment applied to both nostrils and routine soap baths. Samples of bodily fluids will be obtained to assess for MRSA infections, based on the clinical picture. All MRSA positive cultures will then be tested to identify which strain of MRSA is causing the infection. This will be compared to the initial nasal swab to see if these are the same strain of MRSA.

**Progress Reported:** HRPO Log #A-16977.4a. HRPO approval for the lead site was obtained on 1/30/12. Vanderbilt received a determination of “not engaged in research” status because they are examining de-identified microbiology samples and therefore review was not required. The lead site has completed two quarters. A delay in executing a subcontract between Erlanger Health Systems (EHS), the principal medical center where the study is to be undertaken, and the University of Tennessee College Of Medicine lead to a delay in progress. This delay allowed for refinement of the study processes such as screening and enrollment. The last quarterly report dated 8/13/12, stated that subject enrollment was initiated on 5/15/12 with 117 subjects screened and 13. Of the 13 enrolled, 9 have completed the study and the preliminary results look promising. Sub-typing of MRSA at Dr Creech’s laboratory at Vanderbilt University will elucidate trends concerning the effectiveness of decolonization on the various MRSA strands. During the next quarter, the lead site anticipates the addition of the second clinical site and this could potentially double the subject enrollment.

**Project 6:**
**Project Title:** Hepcidin and Anemia in Trauma
**Principal Investigator:** Lena M. Napolitano, MD
**Lead Site:** University of Michigan Health System, Ann Arbor MI

**Lay Abstract:** Anemia (low hemoglobin and red blood cell count) is common in trauma patients and is associated with a high rate of blood transfusion. Anemia is a problem in trauma patients, particularly in the recovery phase, since it can inhibit trauma patients from participating in physical therapy. This study is designed to determine how long anemia persists in trauma patients and why anemia does not resolve. Hepcidin, a peptide made in the liver, has recently been identified as the key regulator of iron homeostasis, and plays a major role in how and why anemia develops. Hepcidin reduces iron availability by: (1) decreased iron absorption across the intestine and (2) decreased release of iron—iron is locked in the cells and not available to make red blood cells. High levels of hepcidin induce a state of functional iron deficiency. Hepcidin is
increased in states of inflammation, and likely plays an important role in the acute inflammation that occurs with trauma. However, no studies have measured hepcidin in trauma patients. If hepcidin levels are elevated in trauma, this will confirm that inability to use iron stores is key to the anemia of trauma. Dr Napolitano suspects that hepcidin will be increased early after trauma and that anemia will not resolve in trauma until late. By measuring changes in red blood cells, hepcidin and other markers of inflammation in trauma patients she can critically examine potential therapeutic strategies for the treatment and of anemia in trauma and critical care.

**Progress Reported:** HRPO Log #A-16977.8. HRPO approval was obtained on 3/30/12. This site has completed two quarters. In the last quarterly report dated 10/10/12, there were 47 subjects screened with 12 subjects enrolled. The inclusion criteria of a hematocrit less than 34.5% during the first 24 hours after admission, has slowed enrollment, so a protocol amendment has been submitted to extend the time frame to the first 72 hours after admission. This protocol modification will likely increase the potential subject enrollment.

**Project 7:**

**Project Title:** Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia after Severe Trauma  
**Principal Investigator:** Jean-Francois Pittet, MD  
**Lead Site:** University of Alabama at Birmingham  
**Lay Abstract:** This project will examine the effect of antioxidant vitamins (vitamins C and E) on patients who suffer severe trauma and have severe bleeding. Recent clinical studies have demonstrated that patients with severe bleeding from trauma do not coagulate or clot normally before they are treated. This PI has previously shown that one of the major reasons why these trauma patients do no coagulate normally is specific derangements with the protein (protein C) that normally prevents unwanted spontaneous formation of blood clot in the vessels. Antioxidant vitamins C and E have been shown to reduce mortality, organ failure and surgical site infections in trauma patients and to attenuate the procoagulant activity associated with the acute response in humans. This project proposes to determine whether the administration of a low-cost and safe therapy, i.e. antioxidant vitamins C and E, given early after severe trauma would attenuate the posttraumatic coagulation derangements and significantly decrease lung infections in trauma patients. The results obtained may help to find new treatments that may reduce the severity of bleeding and infection after trauma in humans.

**Progress Reported:** HRPO Log# A-16977.6. Approval for this project was obtained on 8/16/2012. The subcontract was executed and the Principal Investigator reports study initiation is currently in progress.

**Project 8:**

**Project Title:** Thrombelastography (TEG®) based dosing of enoxaparin for thromboprophylaxis: a prospective randomized trial  
**Principal Investigator:** Martin A. Schreiber, MD  
**Lead Site:** Oregon Health & Science University (OHSU)  
**Participating Sites:** University of Texas Health Science Center at Houston, and University of California San Francisco (UCSF)  
**Lay Abstract:** The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many times Lovenox is given to patients who are at a higher risk of developing clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not fully prevent
the development of these clots especially in critically ill or obese patients. Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography (TEG) can be used to measure how blood clots. The purposes of this study are to: a) learn if the TEG can better guide physicians in prescribing an effective dose of Lovenox compared to standard doses in preventing blood clots from developing in the legs and lungs, b) compare the development of blood clots in patients receiving the standard dose to patients receiving a TEG guided dose of Lovenox, and c) determine if TEG guided dosing results in decreased bleeding complications compared to standard dosing. Enrolled patients will be randomized to receive the standard dose ordered by their doctor or to have their dose modified based on the TEG results. Patients will have up to 1 teaspoon of blood drawn as often as daily or as infrequently as two times a week until the medicine is stopped or until they are discharged from the hospital. We will compare incidence of blood clots formed and bleeding complications between the 2 groups of patients to determine if TEG modified dosing relates to a lower rate of blood clots in critically ill patients.

Progress Reported: HRPO Log #A-16977.7a. HRPO approval was obtained on 9/10/2012. The subcontract was executed and the Principal Investigator reports study initiation is currently in progress.

Project 9:
Project Title: Delayed Splenic Rupture after Non-Operative Management of Blunt Splenic Injury; an American Association for the Surgery of Trauma (AAST) Multi-Institutional Prospective Trial
Principal Investigator: Ben Zarzaur, MD
Lead Site: University of Tennessee at Memphis
Participating Sites: University of California at San Diego (UCSD), University of Texas Health Science Center San Antonio (UTHSCSA), University of Pittsburgh –Mercy Hospital, University of Pittsburgh–Presbyterian Hospital: University of Texas Health Science Center at Houston (UTHSC-Houston), University of Florida Health Science Center at Jacksonville, Yale School of Medicine, Case Western Reserve, Adams Cowley Shock Trauma Center, Medical College of Wisconsin (MCW).

Lay Abstract: Nearly 39,000 adults will suffer a blunt splenic injury (BSI) this year from incidents such as car crashes and falls. Current guidelines suggest that if a patient with a BSI has a good heart rate and good blood pressure that he or she does not have to go immediately to the operating room to have the spleen removed. However, over 10% of patients managed this way will have to undergo spleen removal within 5 days of injury because the spleen will begin to severely bleed. The greater risk, though, may be to patients who are discharged from the hospital after only a few days. These patients may suffer sudden spleen rupture in the outpatient setting. The 6-month risk of spleen removal after discharge with BSI is thought to be less than 2%. But, the exact rate is not known because no one has tried to follow patients with BSI for a full 6 months after injury to determine what will happen. In this research the PI’s plan to follow 1000 patients with BSI from 11 trauma centers across the country for 6 months. By doing this, the investigators will obtain an accurate estimate of the 6 month risk of spleen rupture after BSI. The investigators will also be able to determine factors associated with delayed splenic rupture. They will be able to determine which of the several treatments are best for patients with a BSI. This research will be significant because it is expected to lead to the development of strategies that will result in subjecting adults with BSI to the least risk while preserving the most spleens.
**Progress Reported:** Each site has obtained HRPO approval and contracting is in place. Each site is actively enrolling. Data listed below (Table 1) is current as of 10/9/12. All sites participate in routine conference calls to address study issues.

Table 1: Site status for Delayed Splenic Rupture after Non-Operative Management of Blunt Splenic Injury; an American Association for the Surgery of Trauma (AAST) Multi-Institutional Prospective Trial.

<table>
<thead>
<tr>
<th>HRPO Log#</th>
<th>Site PI</th>
<th>Site</th>
<th># of subjects screened</th>
<th># of subjects enrolled</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-16977.3a</td>
<td>Ben Zarzaur, MD</td>
<td>UTenn Memphis</td>
<td>103</td>
<td>46</td>
</tr>
<tr>
<td>A-16977.3b</td>
<td>Raul Coimbra, MD</td>
<td>UCSD</td>
<td>16</td>
<td>3</td>
</tr>
<tr>
<td>A-16977.3c</td>
<td>John Myers, MD</td>
<td>UTHSC-San Antonio</td>
<td>65</td>
<td>41</td>
</tr>
<tr>
<td>A-16977.3d</td>
<td>Aaron Scifres, MD</td>
<td>UPitt-Mercy Hospital</td>
<td>12</td>
<td>11</td>
</tr>
<tr>
<td>A-16977.3e</td>
<td>Louis Alarcon, MD</td>
<td>UPitt-Presbyterian</td>
<td>31</td>
<td>17</td>
</tr>
<tr>
<td>A-16977.3f</td>
<td>Rosemary Kozar, MD</td>
<td>UTHSC-Houston</td>
<td>81</td>
<td>37</td>
</tr>
<tr>
<td>A-16977.3g</td>
<td>Andrew Kerwin, MD</td>
<td>Univ of Florida-Jacksonville</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>A-16977.3h</td>
<td>Adrian Maung, MD</td>
<td>Yale School of Medicine</td>
<td>28</td>
<td>12</td>
</tr>
<tr>
<td>A-16977.3i</td>
<td>Jeffrey Claridge, MD</td>
<td>Case Western Reserve</td>
<td>25</td>
<td>24</td>
</tr>
<tr>
<td>A-16977.3j</td>
<td>Thomas Scalea, MD</td>
<td>Adams Cowley Shock Trauma</td>
<td>58</td>
<td>13</td>
</tr>
<tr>
<td>A-16977.3k</td>
<td>Todd Neideen, MD</td>
<td>Medical College of Wisconsin</td>
<td>44</td>
<td>17</td>
</tr>
</tbody>
</table>

**Total =** 473 screened, 225 enrolled

**B. The contractor will provide multiple meeting forums for progress towards methods for military-civilian transfer of medical advances, and development of clinical protocols from promising currently funded pilot studies, as determined by the Science Committee. These meetings will include military and civilian researchers.**

As indicated in a previous report, registration for the NTI conference, originally planned for May 2012, remained extremely low, giving NTI no choice but to cancel the conference.

In place of the original trauma conference, on May 10, 2012 the NTI Science Committee and NTI Board members met in San Antonio at the Grand Hyatt Hotel. The primary purpose of the meeting was to have the Principal Investigator’s funded by this grant present their current research progress and status. In addition, PI’s were asked to propose follow-on studies. Ideas for follow-on studies were discussed by the Board and three follow-on studies were selected that, could be developed with NTI assistance into full proposals for submission to funding agencies or for development for NTI foundation grants. Collaboration among investigators was encouraged at this closed meeting.
Table 2: Overall Award Milestones

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Planned Date</th>
<th>Actual Date</th>
<th>Projected Completion Date</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepare and Issue RFP</td>
<td>Yr1Qtr1</td>
<td>Yr1Qtr1</td>
<td>N/A</td>
<td>Completed</td>
</tr>
<tr>
<td>NTI Board Science Committee Review and Select Proposals for Funding</td>
<td>Yr1Qtr1</td>
<td>Yr1Qtr1</td>
<td>N/A</td>
<td>Completed</td>
</tr>
<tr>
<td>Award Grants</td>
<td>Yr1Qtr1</td>
<td>Yr1Qtr1</td>
<td>N/A</td>
<td>Completed</td>
</tr>
<tr>
<td>Contract with Awardee Organization</td>
<td>Yr1Qtr1</td>
<td>Ongoing</td>
<td>Term of the Contract</td>
<td>Ongoing; 18 of 19 complete</td>
</tr>
<tr>
<td>Manage Compliance of Awards</td>
<td>Ongoing</td>
<td>Ongoing</td>
<td>Term of the Contract</td>
<td>Ongoing</td>
</tr>
<tr>
<td>Provide meeting forums</td>
<td>Ongoing</td>
<td>Ongoing</td>
<td>Yr2Qtr4</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

KEY RESEARCH ACCOMPLISHMENTS
None at this time

REPORTABLE OUTCOMES
None at this time

CONCLUSION
NTI has successfully completed a RFP, peer-reviewed process, with selection of nine relevant trauma projects. We are conducting on-going oversight of each project under this award. Each of the funded projects is of critical importance in the advancement of trauma care. Traumatic injury, hemorrhage and ongoing management of the trauma patient with infection, anemia, and bleeding complications have the potential to have a long lasting impact on outcomes for trauma patients.

NTI continues to seek opportunities to provide meetings for progress towards methods for military-civilian transfer of medical advances, and development of clinical protocols from promising currently funded pilot studies, as determined by the Science Committee.
ABBREVIATIONS

AAST   American Association for the Surgery of Trauma
ALI    Acute lung injury
ALIVE  Acute Lung Injury Ventilation Evaluation
APRV   airway pressure release ventilation
ARDSNet Acute Respiratory Distress Syndrome Network
BMC    Boston Medical Center
BSI    Blunt Splenic Injury
CT     computed tomography
DNA    Deoxyribonucleic acid
EHS    Erlanger Health System
FWB    Fresh Whole Blood
HRPO   Human Research Protection Office
HSPS   Human Subjects Protection Scientists
ICD    International Classification of Diseases
ICU    Intensive Care Unit
IRB    Institutional Review Board
MCW    Medical College of Wisconsin
MRSA   Methicillin-resistant Staphylococcus aureus
NTI    National Trauma Institute
OHSU   Oregon Health & Science University
OR     Operating Room
PI     Principal Investigator
RBCs   Red Blood Cells
RFP    Request for Proposal
SAMMC  San Antonio Military Medical Center
SOM    School of Medicine
TEG    Thrombelastography
UTHSC  University of Tennessee Health Science Center
UTHSC-Houston University of Texas Health Science Center at Houston
UTHSCSA University of Texas Health Science Center at San Antonio
UCLA   University of California, Los Angeles
UCSD   University of California, San Diego
UCSF   University of California, San Francisco
UPitt  University of Pittsburgh
USAISR United States Army Institute of Surgical Research
REPORT OF INVENTIONS AND SUBCONTRACTS

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Department of Defense, Executive Services Directorate (700D/0281). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

 PLEASE DO NOT RETURN YOUR COMPLETED FORM TO THE ABOVE ORGANIZATION. RETURN COMPLETED FORM TO THE CONTRACTING OFFICER.

1. NAME OF CONTRACTOR/SUBCONTRACTOR: National Trauma Institute
   a. ADDRESS (include ZIP Code): 8000 IH 10 West, Suite 600
      San Antonio, TX 78230

2. CONTRACT NUMBER: W81XWH-11-1-0841
   a. AWARD DATE: 20110929
   b. NAME OF GOVERNMENT PRIME CONTRACTOR: Same
   c. CONTRACT NUMBER: Same

3. TYPE OF REPORT or one:
   a. INTERIM
   b. FINAL

SECTION I - SUBJECT INVENTIONS

5. SUBJECT INVENTIONS REQUIRED TO BE REPORTED BY CONTRACTOR/SUBCONTRACTOR: If "Name, as stated"

   NAME(S) OF INVENTOR(S):
   a. First, Middle Initial

   TITLE OF INVENTION:

   DISCLOSURE NUMBER:

   PATENT APPLICATION SERIAL NUMBER OR PATENT NUMBER:

   ELECTION TO FILE PATENT APPLICATION(s):
   a. UNITED STATES
   b. FOREIGN

   CONFIRMATORY INSTRUMENT OR ASSIGNMENT FORWARDED TO CONTRACTING OFFICER:
   a. YES
   b. NO

   ELECTED FOREIGN COUNTRIES IN WHICH A PATENT APPLICATION WILL BE FILED:
   a. United States
   b. Foreign countries of patent application

1. EMPLOYER OF INVENTOR(s) NOT EMPLOYED BY CONTRACTOR/SUBCONTRACTOR:
   a. NAME OF INVENTOR (Last, First, Middle Initial)
   b. NAME OF EMPLOYER
   c. ADDRESS OF EMPLOYER (Include ZIP Code)

6. SUBCONTRACTS AWARDED BY CONTRACTOR/SUBCONTRACTOR: If "Name, as stated"

   NAME OF SUBCONTRACTOR(S):
   University of Tennessee
   Health Science Center
   University of California San Diego

   ADDRESS (include ZIP Code):
   a. 910 Madison Avenue, 2nd floor, Memphis, TN 38113
   b. 200 W. Arbor Drive 8220

   SUBCONTRACT NUMBER(S):
   NCH-10-020a
   NCH-10-020b

   PATENT RIGHTS:
   a. Clause
   b. Date (MM/DD/YYYY)

   DESCRIPTION OF WORK TO BE PERFORMED UNDER SUBCONTRACT(S):
   University of Tennessee
   Medical research: Delayed splenic rupture after non-operative management
   University of California San Diego
   Medical research: Delayed splenic rupture after non-operative management

SECTION III - CERTIFICATION

7. CERTIFICATION OF REPORT BY CONTRACTOR/SUBCONTRACTOR: (Not required if "Name, as stated"
   SMALL BUSINESS or X NONPROFIT ORGANIZATION

   I certify that the reporting party has procedures for prompt identification and timely disclosure of "Subject Inventions," that such procedures have been followed and that all "Subject Inventions" have been reported.

   NAME OF AUTHORIZED CONTRACTOR/SUBCONTRACTOR (Last, First, Middle Initial)

   TITLE

   SIGNATURE

   DATE SIGNED

DD FORM 882, JUL 2005
PREVIOUS EDITION IS OBSOLETE.
<table>
<thead>
<tr>
<th>6a. Name</th>
<th>b. Address</th>
<th>c. Subcontract number</th>
<th>d. (1) clause number</th>
<th>e. Description of work to be performed under subcontracts</th>
<th>f.(1) award dates</th>
<th>f.(2) estimated completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>University of Texas Health Science Center at San Antonio</td>
<td>7703 Floyd Curl Drive, MC 7740, San Antonio, TX 78229-3900</td>
<td>NCH-10-020c</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20110929</td>
<td>20130928</td>
</tr>
<tr>
<td>University of Pittsburgh</td>
<td>123 University Place, Lower Level, Pittsburgh, PA 15213</td>
<td>NCH-10-020d</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120529</td>
<td>20130528</td>
</tr>
<tr>
<td>University of Pittsburgh</td>
<td>123 University Place, Lower Level, Pittsburgh, PA 15213</td>
<td>NCH-10-020e</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20130126</td>
<td>20130125</td>
</tr>
<tr>
<td>University of Texas Health Science Center</td>
<td>7000 Fannin, Suite 1006, Houston TX 77030</td>
<td>NCH-10-020f</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120130</td>
<td>20130129</td>
</tr>
<tr>
<td>University of Florida Board of Trustees</td>
<td>210 Grinter Hall PO Box 115500, Gainesville, FL 32615500</td>
<td>NCH-10-020g</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120315</td>
<td>20130314</td>
</tr>
<tr>
<td>Yale University</td>
<td>47 College Street, Ste 203, New Haven, CT 06520-0847</td>
<td>NCH-10-020h</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120109</td>
<td>20130108</td>
</tr>
<tr>
<td>Medical College of Wisconsin</td>
<td>8701 Watertown Plank Road, Milaukee, WI 53226-0509</td>
<td>NCH-10-020k</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120327</td>
<td>20130326</td>
</tr>
<tr>
<td>The MetroHealth System</td>
<td>2500 MetroHealth Drive, Cleveland, OH 44109-1900</td>
<td>NCH-10-020i</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120214</td>
<td>20130213</td>
</tr>
<tr>
<td>University of Maryland Baltimore</td>
<td>620 Lexington Street, 4th floor, Baltimore, MD 21201</td>
<td>NCH-10-020j</td>
<td></td>
<td>Medical research: Delayed splenic rupture after non-operative management</td>
<td>20120214</td>
<td>20130213</td>
</tr>
<tr>
<td>6a. Name</td>
<td>b. Address</td>
<td>c. Subcontract number</td>
<td>d. (1) clause number</td>
<td>d.(2) date</td>
<td>e. Description of work to be performed under subcontracts</td>
<td>f.(1) award dates</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>----------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Christiana Care Health Services</td>
<td>4755 Ogletown-Stanton Road, Newark, DE 19718-0002</td>
<td>NTI-10-011</td>
<td></td>
<td></td>
<td>Medical research: the safety and efficacy of platelet transfusion in patients receiving antiplatelet therapy that sustain intracranial hemorrhage</td>
<td>20120404</td>
</tr>
<tr>
<td>University of Alabama at Birmingham</td>
<td>1702 2nd Ave. South AB 1120 35294-0111, Birmingham, AL 35294</td>
<td>NCH-10-013</td>
<td></td>
<td></td>
<td>Medical research: Effect of antioxidant vitamins on coagulopathy and nosocomial pneumonia after severer trauma</td>
<td>20120816</td>
</tr>
<tr>
<td>University of California San Diego</td>
<td>200 W. Arbor Drive #8896, San Diego, CA 92103-8896</td>
<td>NCH-10-016</td>
<td></td>
<td></td>
<td>Medical research: Detection and management of non-compressible hemorrhage by vena cava ultrasonography</td>
<td>20111117</td>
</tr>
<tr>
<td>The Regents of the University of California</td>
<td>1100 Kinross Avenue, Suite 211, Los Angeles, CA 90095-1406</td>
<td>NCH-10-033</td>
<td></td>
<td></td>
<td>Medical research: Transfusion of stored fresh whole blood in a civilian trauma center</td>
<td>20120306</td>
</tr>
<tr>
<td>University of Tennessee</td>
<td>62 S. Dunlap, Suite 300, Memphis TN 38163</td>
<td>TRA-10-020</td>
<td></td>
<td></td>
<td>Medical research: Acute lung injury ventilation evaluation (ALIVE) trial</td>
<td></td>
</tr>
<tr>
<td>Oregon Health &amp; Science University</td>
<td>3181 SW Sam Jackson Park Road, L611, Portland, OR 97239</td>
<td>NCH-10-053</td>
<td></td>
<td></td>
<td>Medical research: Thrombelastography (TEG) based dosing of enoxaparin for thromboprophylaxis</td>
<td>20120910</td>
</tr>
<tr>
<td>The Regents of the University of Michigan</td>
<td>1068 Wolverine Tower, 303 South State Street, Ann Arbor, MI 48109-1274</td>
<td>TRA-10-037</td>
<td></td>
<td></td>
<td>Medical research: Hepcidin and anemia in trauma</td>
<td>20120330</td>
</tr>
<tr>
<td>University of Pittsburgh</td>
<td>123 University Place, Lower Level, Pittsburgh, PA 15213</td>
<td>TRA-10-020</td>
<td></td>
<td></td>
<td>Medical research: Characterization of the effects of early sex-hormone environment following injury</td>
<td>20120701</td>
</tr>
</tbody>
</table>
FEDERAL FINANCIAL REPORT

(Follow form instructions)

1. Federal Agency and Organizational Element to Which Report is Submitted
DOD, USAMRAA

2. Federal Grant or Other Identifying Number Assigned by Federal Agency (To report multiple grants, use FFR Attachment)
W81XWH-11-1-0841

3. Recipient Organization (Name and complete address including Zip code)
National Trauma Institute, 8000 IH 10 W, Suite 600, San Antonio, Texas, 78230

4a. DUNS Number
800219185

4b. EIN
32-0170279

5. Recipient Account Number or Identifying Number (To report multiple grants, use FFR Attachment)

6. Report Type
☐ Quarterly
☐ Semi-Annual
☐ Annual
☐ Final
☒ Cash ☐ Accrual

7. Basis of Accounting

8. Project/Grant Period
From: (Month, Day, Year) 09/28/2011
To: (Month, Day, Year) 09/30/2012

b. Reporting Period End Date
(Month, Day, Year) 09/30/2012

10. Transactions
Cumulative

(Use lines a-c for single or multiple grant reporting)

Federal Cash (To report multiple grants, also use FFR Attachment):

| a. Cash Receipts | $3,845,000 |
| b. Cash Disbursements | $902,911 |
| c. Cash on Hand (line a minus b) | $2,942,089 |

(Use lines d-o for single grant reporting)

Federal Expenditures and Un obligated Balance:

| d. Total Federal funds authorized | $3,845,000 |
| e. Federal share of expenditures | $902,911 |
| f. Federal share of unliquidated obligations | $2,087,379 |
| g. Total Federal share (sum of lines e and f) | $2,990,290 |
| h. Un obligated balance of Federal funds (line d minus g) | $854,710 |

Recipient Share:

| i. Total recipient share required | |
| j. Recipient share of expenditures | |
| k. Remaining recipient share to be provided (line i minus j) | |

Program Income:

| l. Total Federal program income earned | $450 |
| m. Program income expended in accordance with the deduction alternative | |
| n. Program income expended in accordance with the addition alternative | |
| o. Unexpended program income (line l minus line m or line n) | $450 |

11. Indirect Expense

| a. Type | b. Rate | c. Period From | Period To | d. Base | e. Amount Charged | f. Federal Share |
| g. Totals | $757,656 | $189,414 | $189,414 |

12. Remarks: Attach any explanations deemed necessary or information required by Federal sponsoring agency in compliance with governing legislation:

By signing this report, I certify to the best of my knowledge and belief that the report is true, complete, and accurate, and the expenditures, disbursements and cash receipts are for the purposes and intent set forth in the award documents. I am aware that any false, fictitious, or fraudulent information may subject me to criminal, civil, or administrative penalties. (U.S. Code, Title 18, Section 1001)

13. Certification: By signing this report, I certify to the best of my knowledge and belief that the report is true, complete, and accurate, and the expenditures, disbursements and cash receipts are for the purposes and intent set forth in the award documents. I am aware that any false, fictitious, or fraudulent information may subject me to criminal, civil, or administrative penalties. (U.S. Code, Title 18, Section 1001)

a. Typed or Printed Name and Title of Authorized Certifying Official
Monica Phillips

b. Signature of Authorized Certifying Official

14. Agency use only:

Standard Form 425 - Revised 6/28/2010
OMB Approval Number: 0348-0061
Expiration Date: 10/31/2011

Paperwork Burden Statement
According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless it displays a valid OMB Control Number. The valid OMB control number for this information collection is 0348-0061. Public reporting burden for this collection of information is estimated to average 1.5 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0061), Washington, DC 20503.